SciClone Stock Hits New 52-Week High (SCLN)

NEW YORK ( TheStreet) -- SciClone Pharmaceuticals (Nasdaq: SCLN) hit a new 52-week high Monday as it is currently trading at $7, above its previous 52-week high of $6.97 with 296,592 shares traded as of 12:05 p.m. ET. Average volume has been 492,500 shares over the past 30 days.

SciClone has a market cap of $385.1 million and is part of the health care sector and drugs industry. Shares are up 46.9% year to date as of the close of trading on Friday.

SciClone Pharmaceuticals, Inc. provides therapies for the treatment of oncology, infectious diseases, cardiovascular, urological, respiratory, and central nervous system disorders in the People's Republic of China and internationally. The company has a P/E ratio of 11.9, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates SciClone as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. You can view the full SciClone Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.
null

If you liked this article you might like

Drug Price Inflation and a Patent Cliff Could Trigger a Wave of Deals in Generic Drugs Space

Merck Up on Approval, Teva Sinks on Earnings and Asset Sales: Biotech Movers

Today's Weak On High Volume Stock: SciClone Pharmaceuticals (SCLN)

SciClone Pharmaceuticals (SCLN): Today's Weak On High Volume Stock

Jim Cramer's 'Mad Money' Recap: Here's This Week's Game Plan